The human pancreatic elastase I gene is transcriptionally silent, despite the apparent integrity of the structural gene. The transcriptional regulatory sequences necessary and sufficient for transcription of the active rat homologue are localized within 205 base pairs (bp) of the transcriptional start and comprise a pancreas-specific transcriptional enhancer of 134 bp immediately upstream of a 71 bp non-specific promoter. The human gene has 58 nucleotide differences within this region, 13 of which are in the three functional elements (A, B and C) that constitute the enhancer. Through cell transfection analyses with a pancreatic acinar tumor cell line, we show that the nucleotide differences in the human 5′ flanking gene sequences have inactivated both the enhancer and the promoter. The changes in the three elements of the human enhancer alone are sufficient to inactivate the enhancer; conversely, restoring these to the rat configuration partially restores the activity of the human enhancer. The two mutations in the A element and the four mutations in the B element abolish the binding of the transcription factors previously shown to mediate the activity of these elements. Replacing the active 71 bp rat promoter with the human promoter also prevents expression. Therefore, the evolutionary silencing of the human elastase I gene appears due to mutations that inactivate crucial enhancer and promoter elements.
INTRODUCTION
The evolution of genomes is a continual process of the formation, duplication, modification, and inactivation of genes. Whereas the inactivation of a single copy, essential gene would have a dramatic phenotypic effect, the inactivation of a non-essential gene may have little or no obvious phenotypic effect. The inactivation of a member of a gene family, for example, may have little effect if the function of that gene is redundant with that of other family members.
Six pancreatic elastase-like enzymes are commonly expressed to high levels selectively in the mammalian exocrine pancreas (1) (2) (3) (4) (5) . Of these six, elastase I is the major protease with elastin-degrading activity. Not all mammals express all six pancreatic elastases, however. For example, human pancreas is devoid of the archetypal elastase I enzyme (6, 7) .
The human elastase I gene (ELA1) has been cloned (6), sequenced (8) , and positioned on chromosome 12q13 (9) . The nucleotide sequences of the exons of the human ELA1 are 88% and 89% identical to those of the porcine and rat elastase I genes, respectively. The exon sequences appear to be intact and encode a protein with an amino acid sequence 89% identical to that of the rat and pig enzymes. The human coding region is devoid of stop codons or other changes that would prevent the synthesis of a functional enzyme. Moreover, the exon/intron boundaries conform to the consensus sequences required for RNA splicing. However, the mRNA for ELA1 is not detectable in human pancreatic RNA preparations either by hybridization analyses (6, 8) or by sensitive RT-PCR (8) . Therefore, the defect in ELA1 expression appears to be either transcriptional or in a step in RNA processing other than splicing that prevents the accumulation of mature mRNA.
In contrast to the exonic sequences, the 5′ and 3′ flanking sequences of the human ELA1 gene are less well conserved when compared to those of the active rat gene. The proximal 205 bp of flanking DNA containing the transcriptional control elements of the rat gene differ by 28% from the corresponding human region; further upstream between -206 and -500 the sequences are not significantly related (68% different) (6) . Therefore, the accumulation of nucleotide changes in transcriptional control elements may have led to the transcriptional inactivation of the human gene.
We sought to identify the defects in the human gene that prevent its expression. For the homologous, but active, rat ELA1 gene the regulatory sequences necessary and sufficient for pancreatic transcription reside within 205 bp immediately upstream of the transcriptional start site (10) . This regulatory region comprises a transcriptional enhancer between -205 and -72, which contains all the regulatory information necessary for organ-specific transcription in transgenic mice (11) , and a minimal promoter between -71 and +8, which responds to the enhancer but does not contribute to organ-specificity (11, 12) . The enhancer contains three functional elements (designated A, B and C) necessary for the correct cell-and organ-specific expression of a reporter *To whom correspondence should be addressed. Tel: +1 214 648 1923; Fax: +1 214 648 1915; Email: ray@hamon.swmed.edu Figure 1 . Nucleotide differences between the active rat and the inactive human ELA1 genes present in the proximal 5′ gene flanking region harboring key transcriptional control elements. Only the nucleotides that differ from the rat sequence are shown for the human sequence. The rat enhancer region has been mapped from -205 to -72 and the promoter region from -71 to +8. The functionally important A, B and C elements of the rat enhancer are boxed. The rat ELA1 gene sequence is from Swift et al. (25) and the human sequence from Tani et al. (6) . transgene in mice (13) . The A and B elements bind pancreasspecific transcription factors that mediate the cell-specific activity of the enhancer (14) (15) (16) ; the C element augments the strength of the enhancer activity in combination with the A and B elements (17) . Mutations within any one of the three elements inactivate the rat elastase I enhancer when tested by transient or stable transfection assays in mouse 266-6 or rat AR4-2J pancreatic acinar cell lines (13, 18) ; mutation of any two is required to inactivate the enhancer in transgenic mice (13) . Therefore, the enhancer is required for transcription of the rat elastase I gene, and the A, B and C elements are crucial for the activity of the enhancer.
We tested whether the nucleotide differences between the human and rat enhancer/promoter region prevent transcription of the human gene. Both the enhancer and promoter regions are defective when tested by transfection into cultured pancreatic acinar tumor cells. Nucleotide differences between the human and rat A, B and C enhancer elements alone are sufficient to abolish transcriptional activity of the enhancer. The differences in the A and B elements prevent the binding of the transcription factors that mediate the activity of these two elements. Therefore, it appears that the silence of the human EI gene is due to the mutation of binding sites for organ-specific transcription factors.
RESULTS
The 5′ proximal flanking sequence of the rat ELA1 gene from -205 to +8 spans the enhancer and promoter region both necessary and sufficient for transcription in cultured pancreatic acinar cells and in the pancreas of transgenic mice (11, 18) . Fifty-eight out of the 213 nucleotide positions of this region differ between the active rat and the inactive human genes (Fig. 1) . Twenty-four differences are within the proximal 71 bp promoter, 13 are in the A, B and C elements of the enhancer, and the remaining 21 are in the enhancer region outside the three elements.
To determine whether these nucleotide differences affect the transcriptional competence of the human ELA1 gene, we compared the transcriptional activities of the enhancer/promoter regions of the human and rat genes. Nucleotides -205 to +8 of the rat gene or -200 to +8 of the human gene were fused to a human growth hormone (hGH) reporter gene and transfected into the mouse pancreatic acinar tumor cell line 266-6 (Fig. 2) . 266-6 cells were derived from a pancreatic acinar cell tumor in a transgenic mouse expressing SV40 T antigen (19) ; in culture these cells retain expression of acinar specific genes such as elastase, trypsin and amylase (13) . We had shown previously that the -205 to +8 enhancer/promoter region of the rat ELA1 activates transcription of the hGH reporter gene in this mouse acinar cell line, but not in a variety of non-acinar cell lines (13, 16, 18) . The rat promoter region without its enhancer is inactive (Fig. 2 , construct rp.hGH). The activity of the entire human enhancer/promoter region (construct he-hp.hGH) was 2.6% that of the homologous rat region (construct re-rp.hGH), which is not significantly more than the activity of the rat promoter region without an enhancer (construct rp.hGH).
Nucleotide differences in the human enhancer and promoter inhibit transcription
The effects of the nucleotide differences in the enhancer and promoter regions were assessed separately. Replacing the rat enhancer (-205 to -72) with the human enhancer region (construct he-rp.hGH) reduced transcriptional activity by 94% (Fig. 2) . The complementary exchange of the human promoter region for the rat promoter (construct re-hp.hGH) had an equally detrimental affect. These results demonstrate that both the promoter and the enhancer of the human gene are defective.
We next tested whether the 13 nucleotide differences in the human A, B and C elements were sufficient to inactivate the enhancer (Fig. 2) . Indeed, introducing the six nucleotide changes in the C element, four in the B and three in the A (construct h/re-rp.hGH) effectively crippled the rat enhancer. These few changes decreased the transcriptional activity of the rat enhancer by 98%, to the level of activity of rp.hGH, which has the enhancer completely deleted.
Repairing the three human enhancer elements to the rat sequence (construct r/he-hp.hGH, Fig. 2 ) was not sufficient to reactivate the entire human enhancer/promoter region, because defects remain in the human promoter domain. However, in combination with the active rat promoter, repairing the three enhancer elements to the rat configuration (construct r/he-rp.hGH) partially restored the activity of the human enhancer domain (Fig. 2) . Therefore, the nucleotide changes in the three elements are sufficient to inactivate the human enhancer, although mutations in the enhancer outside the elements have additional effects. Effects of the nucleotide differences in the human enhancer and promoter on expression in the pancreatic acinar tumor cell line 266-6. The activities of the transfected genes were measured by the level of hGH production and corrected for transfection efficiency by measuring the activity of the co-transfected RSV-mCAT reporter gene as described in Materials and Methods. A schematic of each construct is shown adjacent to its level of activity, with rat ELA1 gene regions represented in white and human ELA1 regions in black. The activity of each construct is reported as a percentage of the rat enhancer and promoter construct re-rp.hGH and is the average of two to five independent transfections. The error bars denote standard deviations.
The nucleotide differences in the human enhancer elements prevent the binding of pancreatic transcription factors
Mutations in the human A and B elements occur within the binding motifs for pancreatic transcription factors that mediate the activities of these elements in the rat gene (15, 16, 20) . Electrophoretic mobility gel shift assays using nuclear extracts from pancreatic tissue or 266-6 acinar tumor cells were performed to assess the affect of individual and cumulative changes in the binding sites. The rat ELA1 A element binds an acinar cell-specific complex designated PTF1 (Fig. 3, lane 1) . PTF1 is a heteromeric complex containing basic helix-loop-helix binding proteins (21, 22) . The 21 bp minimal binding site for PTF1 comprises two motifs: the E box, characteristic of binding sites for basic helix-loop-helix proteins, and box A (Fig. 3, bottom) . Mutations in either the E box (Fig. 3, lane 5 ) or box A (data not shown) abolish PTF1 binding. The two nucleotide differences in the corresponding 21 bp human A element also eliminate PTF1 binding (Fig. 3,  lane 2) . The third A element mutation lies outside the 21 bp minimal binding site and was not tested. When tested individually, the C (rat) to T (human) change alone in the E box is sufficient to prevent the binding of PTF1 (lane 3), whereas the C to A change between the E and A boxes has no effect (lane 4). Similar results were obtained using nuclear extracts obtained from the pancreatic acinar cell line 266-6 (data not shown). These results indicate that PTF1 cannot bind to the human A element.
A similar analysis was performed for the human ELA1 B element. Gel shift assays using nuclear extracts from 266-6 cells detect the formation of three complexes of distinct electrophoretic mobility with the functional rat B element (Fig. 4,  lane 1) . The C complex is a heterodimer of the pancreatic homeodomain protein PDX1 and a homeodomain protein of the widely expressed PBX family (20; G.Swift, Y.Liu, S.D.Rose and R.J.MacDonald, unpublished observations). The nucleotide sequence requirements for C complex formation are congruent with those necessary for the acinar activity of the B element in the context of the enhancer (20) . The L complex corresponds to the Although the L complex can form on the human B element with 266-6 nuclear extracts, no C complex can be detected (Fig. 4,  lane 2) . When the four base changes between the human and rat are tested individually, only one had a strong adverse effect on the formation of the C complex. The A (rat) to C (human) change abolished binding (Fig. 4, lane 4) . The T to A change actually increased slightly the ratio of the C (active) complex to the L complex (lane 3). The G 1 to T 1 substitution decreased the relative amount of the C complex slightly (lane 5), whereas the G 2 to T 2 change had no discernible effect on the ratio of C and L complexes (lane 6). Even though the A to C change eliminated the L complex, in combination with the G 1 to T 1 change it created a strong binding site for the L complex (lane 7) and recreated the binding pattern of the human B element (lane 2). While the A to C plus G 1 to T 1 combination destroyed the original binding site for PDX1, and thereby the formation of the PDX1/PBX (C) complex as well, it also created another PDX1 site (in the opposite strand, ...TAATG...), which explains the reappearance of the L complex when these two mutations are combined (lane 7). These results demonstrated that the human ELA1 B element is incapable of binding the C complex of transcription factors, which is necessary for the acinar activity of the B element in the context of the enhancer.
DISCUSSION
Kawashima et al. (8) proposed several possible causes for the transcriptional silence of the human ELA1 gene, including the presence of an upstream silencer, loss of elastase-gene specific transcription factors in human acinar cells, and repressive chromosomal position effects, as well as deleterious effects of point mutations in the human enhancer or promoter regions. In this report we demonstrated that mutations in the enhancer and promoter regions are sufficient to prevent the transcription of the human ELA1 gene. Mutations in two crucial elements of the human enhancer prevent the binding of the transcription factors previously shown to mediate the activity of these elements.
The A element of the human and rat ELA1 genes is recognizably conserved in the 5′ regulatory regions of eight murine and human genes encoding pancreatic digestive enzymes ( Table 1 ). The A element (consensus: CACCTGtNggTTTCCCa) is an important component for the action of pancreas-specific enhancers in cultured cells (14, 18, 23, 24) and transgenic animals (13) . The first five A elements listed in Table 1 have been shown to be critical components of enhancers through mutational analyses and nuclear protein binding experiments. In addition, a sequence closely related to the consensus is present at similar positions upstream of the genes for mouse and rat pancreatic trypsins (14, 25) . The A element appears to be the principal, and perhaps sole, mediator of acinar cellspecificity of the pancreatic transcriptional enhancers (14, 15, 24) .
The A element encompasses two essential motifs, an E box (CACCTG) and box A (TTTCCC) (21, 24) . The E and A boxes contact different proteins of a heteromeric complex termed PTF1 (21) . In most of the identified A elements, the two motifs are separated by one DNA helical turn; the three amylase genes have a second box A one turn further away ( Table 1 ). The function of the redundant amylase A boxes is unclear, but in cell-free binding assays PTF1 prefers the distal box A (14) . Box A binds a 64 kDa protein subunit of PTF1 that otherwise has not been identified. The E box binds a 48 kDa subunit that is a member of the helix-loop-helix family of transcription factors (22) . The 48 kDa protein is pancreas-specific and appears to determine the acinar cell-specificity of the PTF1 complex. Mutation of either the E or A boxes prevents PTF1 binding and inactivates the A element. Therefore, the E and A boxes of the A element cooperatively bind the pancreas-specific PTF1 factor complex, are conserved among pancreas-specific genes and are crucial for enhancer activity.
The single base pair difference in the human E box motif prevents the binding of PTF1, presumably by making the sequence incompatible with binding the 48 kDa subunit. None of the proven or prospective PTF1 binding sites shown in Table 1 contain this nucleotide difference in the E box motif. It is likely that the inability of PTF1 to bind the human E box contributes to the inactivation of the human enhancer.
The B element of the ELA1 enhancer is not nearly as well defined. In transfected acinar tumor cells, a 13 bp core (CAGATAAAT-GAGT) is required for the B element to be active in the context of the enhancer (20) . Mutations within this core affect the activity of the element in transfected acinar tumor cells and the binding of a pancreas-specific protein complex (the C complex) to the element in parallel. This coincidence suggests that the C complex mediates the activity of the B element in acinar cells (20) . The C complex is a heterodimer of the homeodomain factors PDX1 and a member of the PBX factor family (G.Swift, Y.Liu, S.D.Rose and R.J.MacDonald, unpublished observations). PDX1 was identified as a pancreasspecific transcription factor that binds sites in the insulin and somatostatin promoters (26) (27) (28) . It is a member of the subclass of homeodomain factors that form heterodimers with widely expressed PBX proteins (29) (30) (31) (32) . Peers et al. (33) have shown that PDX1 and PBX1 bind cooperatively to a transcriptional element of the somatostatin gene promoter. The data of Figure 4 show that the nucleotide changes in the human B element disrupt the binding of the PDX1-PBX (the C) complex.
These results show that sequence changes throughout the enhancer/promoter region, and specifically within known functional enhancer elements, are sufficient to render the human ELA1 gene transcriptionally silent. Whereas the exon coding regions of the human ELA1 gene are largely conserved relative to the active rat gene (nearly 90%), the human 5′ flanking sequence, which harbors the potential transcriptional control elements, has accumulated a large number of nucleotide changes. The nucleotide sequence of the 200 bp remnant of the enhancer/promoter region for the human gene differs by 25% from that of the rat, and the 300 bp immediately upstream of that has no significant sequence conservation. Moreover, there is no significant conservation in the 3′ untranslated and 3′ flanking regions further than 40 bp downstream of the translational stop codon. Takiguchi and colleagues (6, 8) showed that ELA1 mRNA was not present in all nine pancreatic RNA samples tested; it is possible, though unlikely, that the human ELA1 gene is active in some individuals. Thus, the human ELA1 gene appears to be a transcriptionally inactive pseudogene that still encodes a potentially active protease.
An explanation for the dissimilar rates of divergence of the protein coding region compared to the 5′ and 3′ flanking sequences is not readily apparent. The significantly fewer differences in the coding sequences compared to the regulatory sequences and the maintenance of an open reading frame suggest that there was selective pressure to maintain the encoded protein even though it was not expressed in the pancreas. It is possible that there was, or perhaps still remains, an unknown yet important site of expression of elastase I in addition to the pancreas. In this instance an active enzyme may have been maintained at this site while pancreatic expression was lost.
The timing of the evolutionary loss of pancreatic ELA1 expression is not known. It would be informative to determine at what point in phylogeny the ELA1 gene was silenced and whether this silencing can be correlated with the inactivating mutations in the transcriptional enhancer and promoter.
MATERIALS AND METHODS

Plasmid constructions
Plasmids for cell transfection were constructed using standard recombinant DNA techniques (34) and site-specific mutagenesis (35) . All transfection plasmids containing ELA1 regulatory sequences used the human growth hormone (hGH) structural gene as the reporter (10, 36) . The plasmid re-rp.hGH, which contains rat ELA1 gene enhancer (re) and rat promoter (rp) regions from -205 to +8, was previously designated -205EI.hGH (16) . The plasmid rp.hGH, which contains the truncated rat ELA1 promoter (rp) region from -71 to +8, has been previously described as E-GH4 (11). he-hp.hGH contains the human ELA1 gene enhancer (he) and human promoter (hp) regions from -204 to +8 that correspond to the rat -205 to +8 region. he-rp.hGH contains the human enhancer region (nucleotides -204 to -69 of the human EI gene) fused to the rat promoter region (nucleotides -71 to +8 of the rat EI gene). re-hp.hGH contains the rat enhancer region (nucleotides -205 to -72) fused to the human promoter region (nucleotides -68 to +8). h/re-rp.hGH has the rat enhancer and promoter regions (-205 to +8) with substitutions that correspond to the changes found in the A, B and C elements of the human enhancer. These changes to the rat sequence are in element A at nucleotides -100, -105 and -113, element B at -145, -150, -153 and -160, and element C at -183, -185, -186, -189, -191 and -196; the enhancer region outside the three elements and the promoter region retain the nucleotide sequence of the rat gene. r/he-hp.hGH and r/he-rp.hGH have the human and rat promoter regions, respectively, linked to the human enhancer with changes to the rat sequence in, and limited to, the A, B and C elements. The rat ELA1 gene segment was derived from the genomic clone λEIb (25) . The human ELA1 gene sequences were assembled by ligation of synthetic double-stranded oligonucleotides.
Transfection of cultured cells
The mouse pancreatic acinar tumor cell line 266-6 (ATCC #CRL 2151) was transfected by the calcium phosphate procedure (37) . The expression of transfected genes was assayed by hGH accumulation in the culture medium (38) using a radioimmunoassay (Nichols Institue, San Juan Capistrano, CA). The expression levels were corrected for variations in the efficiency of transfection efficiency by measuring the activity of a co-transfected Rous sarcoma virus (RSV)-mCAT fusion gene construct (18) and quantitation of chloramphenicol acetyl-transferase activity (39). In the consensus, N is either 1 or 11 (1 turn) nucleotides. The two nucleotide differences in the human elastase I are underlined. The locations are relative to the transcriptional start sites of the genes.
Electrophoretic mobility shift analysis
Nuclear extracts from rat pancreatic tissue were prepared by the method previously described (15, 40) . Nuclear extracts from 266-6 acinar tumor cells were prepared by the method of Dignam et al. (41) . Electrophoretic mobility shift analyses with 40 femtomoles of 32 P-labeled double-stranded oligonucleotides were performed as described by Sawada and Littman (42) for the ELA1 A element and by Swift et al. (20) for the ELA1 B element. The sequences of the blunt-ended, double-stranded oligonucleotides were (template strand):
rELA1 A, 5′-GTCAcCTGTGcTTTTCCCTGC-3′; hELA1 A, 5′-GTCAtCTGTGaTTTTCCCTGC-3′; rELA1 B, 5′-TAtCAGATAaATgAGTTgACT-3′; and hELA1 B, 5′-TAaCAGATAcATtAGTTtACT-3′.
The bases in lower case identify the nucleotide differences between rat and human. The other sequence variants used in the electrophoretic mobility shift experiments of Figures 3 and 4 were made within the context of these 21 bp sequences.
